Order Center
Order Center

Use the Order Center to build a Shopping Cart, view Saved Shopping Carts, Recent Orders and Quotes

MSDS
MSDS

Search for MSDS (Material Safety Data Sheet) by Product Number

Oligo Ordering
Oligo Ordering

Custom Products and Services, including DNA oligos (Primers and Probes), RNA, siRNA, Peptide Libraries and AQUA Peptides

Corporate
Corporate

Sigma-Aldrich is a leading Life Science and High Technology Materials company focused on enabling science to improve the quality of life

Contáctenos
Contáctenos

Contact Customer Service

Productos Regulados
Productos Regulados

Lista de productos controlados

Compra de Carbon Tetrachloride
Compra de Carbon Tetrachloride

Información importante acerca de la compra de Carbon Tetrachloride

Nueva Línea de Reactivos Grado ACS
Nueva Línea de Reactivos Grado ACS

Expandemos nuesto catálogo con una nueva gama de Reactivos Grado ACS. Calidad Sigma-Aldrich sin afectar su Presupuesto

Advanced Structure Search Tool
Advanced Structure Search Tool

Copy and paste, advanced query features, instant structure to name generation, element analysis and more

News & Information

St. Louis, MO - January 9, 2012 Sigma-Aldrich Extends Laboratory Chemicals Contract with Honeywell

Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today it has signed a five-year contract extension with Honeywell for the manufacture and supply of Riedel-de Haën® high purity solvents, Karl Fischer reagents and other laboratory chemicals produced at Honeywell's Seelze, Germany, manufacturing site. The contract extends an existing supply agreement, in place since 1999, through March 31, 2019.

Read More
St. Louis, MO - January 9, 2012 Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services

Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and High Technology company, announced it has signed an agreement to acquire BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash. The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012.

Read More
St. Louis, MO - December 7, 2011 Sigma® Life Science Announces Gene Knockout Rat Models for Cardiovascular, Diabetes and Atherosclerosis Research

Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that Sigma Advanced Genetic Engineering (SAGE™) Labs, an initiative of Sigma Life Science, has made available three genetically modified rat models that exhibit features key to studying conditions such as obesity, diabetes, atherosclerosis, high cholesterol, hypertension and familial hypercholesterolemia. Details on the models are available at www.sageresearchmodels.com/research-models.

Read More
St. Louis, MO - November 29, 2011 Sigma Life Science Launches the Most Comprehensive Antibody Array for Neurodegenerative Disorders and Neuronal Development

Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that Sigma Life Science, its innovative biological products and services research business, launched the Panorama® Neurobiology Antibody Array for fast protein expression analysis of hundreds of signaling targets that are indicative of neuronal health and development. The Panorama Neurobiology Antibody Array assesses a broader range of signaling targets, and is expected to provide the most comprehensive view available of the cell signaling and regulation pathways that are key to neuronal development and neurodegenerative disorders. For more information and a full list of proteins profiled in the array, visit www.sigma.com/arrays.

Read More